Repligen (NASDAQ:RGEN) Shares Gap Down – Time to Sell?

Repligen Co. (NASDAQ:RGEN) shares gapped down prior to trading on Tuesday . The stock had previously closed at $152.81, but opened at $144.61. Repligen shares last traded at $144.27, with a volume of 140,346 shares trading hands.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RGEN. JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group upped their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a report on Tuesday. They issued an “in-line” rating and a $155.00 price target for the company. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Finally, Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Repligen currently has an average rating of “Hold” and an average price target of $178.64.

Repligen Trading Up 0.4 %

The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average of $156.78 and a two-hundred day moving average of $148.46. The stock has a market capitalization of $8.12 billion, a price-to-earnings ratio of -284.08, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. On average, research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Signaturefd LLC raised its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. purchased a new position in shares of Repligen in the fourth quarter valued at $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen in the fourth quarter valued at $29,000. Resources Management Corp CT ADV purchased a new position in shares of Repligen in the third quarter valued at $37,000. Finally, Quarry LP increased its position in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.